EP3642340A1 — Modified l-asparaginase
Assigned to Jazz Pharmaceuticals Ireland Ltd · Expires 2020-04-29 · 6y expired
What this patent protects
The present invention relates to a modified protein which is a combination of (i) an L-asparaginase and (ii) one or more (poly) peptide (s), wherein the (poly) peptide consists solely of proline amino acid residues and alanine. The modified protein can be formed in various ways, …
USPTO Abstract
The present invention relates to a modified protein which is a combination of (i) an L-asparaginase and (ii) one or more (poly) peptide (s), wherein the (poly) peptide consists solely of proline amino acid residues and alanine. The modified protein can be formed in various ways, including by chemical conjugation between L-asparaginase and (poly) peptides or by expression of the modified protein as a fusion protein. The invention also relates to nucleic acids encoding the modified protein, vectors and / or host cells comprising them, as well as methods for their production. The invention further provides compositions comprising the modified protein and their use in medicine, particularly in the treatment of cancer. In another aspect of the invention, L-asparaginase can be derived from Erwinia and / or has at least 85% identity with the amino acid sequence of SEQ ID NO: 1.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.